ArticleFoods (Basel, Switzerland)2025
Dandelion Leaf Aqueous Extract Relieves Hyperuricemia and Its Complications via Modulating Uric Acid Metabolism, Renal Inflammation, and Gut Microbes.
Article in Foods (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- GPR75 mediates hyperuricemia-induced endothelial inflammatory injury via a HOTAIR/miR-141-3p regulatory network.Molecular biology reports · 2026Article
- Structural Characterization and Anti-Inflammatory Activity of a Bioactive Polysaccharide fromFoods (Basel, Switzerland) · 2026Article
- Research progress on the correlation between gut microbiota and the occurrence of hyperuricemia.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Dandelion is an edible and medicinal plant that has beneficial effects in various complex disorders. In this study, we investigated the regulatory effects of dandelion leaf aqueous extract (DAE) on mice with hyperuricemia (HUA) and explored its underlying mechanisms. DAE exhibited a high total phenolic content (363.31 ± 0.61 mg GAC/g) and contained 20 identified polyphenolic compounds. The administration of DAE significantly reduced serum uric acid levels and exerted protective effects on both liver and kidney function in mice with HUA. Mechanistically, DAE inhibited the NLRP3/Caspase-1 and TLR4/MyD88/NF-κB signaling pathways, leading to the downregulated mRNA expression of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), thereby alleviating renal inflammation. Additionally, DAE modulated the gut microbiota composition and increased SCFA-producing bacteria, along with increases in fecal SCFA contents. These findings suggest that DAE effectively mitigates HUA and its associated renal complications by regulating uric acid metabolism, suppressing renal inflammation, and restoring gut microbial homeostasis. Thus, DAE holds promise as a natural adjuvant therapy for HUA and related kidney inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.